



PUBLICATIONS

Physicians and scientists at TissueTech, Inc. are proud to collaborate with their colleagues to conduct clinical research utilizing our CryoTek[®] cryopreserved umbilical cord and amniotic membrane human birth tissue products. The following represents a sampling of these completed studies that have been validated through publication in peer-reviewed scientific journals:

An Open Label Trial of Cryopreserved Human Umbilical Cord in the Treatment of Complex Diabetic Foot Ulcers Complicated by Osteomyelitis. The results of this multicenter, open-label, Phase 2 study suggest that cryopreserved umbilical cord allograft (TTAX01) is a promising therapy for the management of complex, non-healing diabetic foot ulcers complicated by osteomyelitis...[read more](#)

A Retrospective Study of Cryopreserved Umbilical Cord as an Adjunctive Therapy to Promote the Healing of Chronic, Complex Foot Ulcers with Underlying Osteomyelitis. The results from this study suggest that cryopreserved umbilical cord allograft (NEOX[®] CORD 1K) used as an adjunctive tissue therapy in conjunction with surgical debridement, resection of infected bone, open cortex, and antibiotic treatment may be an effective treatment strategy to promote wound healing of complex foot ulcers associated with osteomyelitis...[read more](#)

Effects of Cryopreserved Amniotic Membrane-Umbilical Cord Allograft on Total Ankle Arthroplasty Wound Healing. The results from this prospective, controlled, randomized trial demonstrate adjunctive treatment with umbilical cord allograft (CLARIX[®] CORD) significantly decreased the overall time to skin healing (28.5 days vs 40 days; $p = .03$) after total ankle arthroplasty...[read more](#)

An Open-label, Single-center, Retrospective Study of Cryopreserved Amniotic Membrane and Umbilical Cord Tissue as an Adjunct for Foot and Ankle Surgery. The results from this study demonstrate umbilical cord allograft (CLARIX[®] CORD) significantly supported decreased pain and improved function after foot and ankle surgery...[read more](#)

Injectable Amniotic Membrane/Umbilical Cord Particulate for Knee Osteoarthritis: A Prospective, Single-Center Pilot Study. The results from this prospective study demonstrate amniotic membrane/umbilical cord particulate (CLARIX[®] FLO) significantly contributes to decreased pain at six weeks ($P < 0.01$), 12 weeks ($P < 0.001$), and 24 weeks ($P < 0.001$) in patients with knee osteoarthritis. This pain reduction was associated with a significant improvement in physical function at all time points ($P < 0.05$) and stiffness at 12 weeks ($P = 0.01$)...[read more](#)

Comparison of Cryopreserved Amniotic Membrane and Umbilical Cord Tissue with Dehydrated Amniotic Membrane/Chorion Tissue. The data demonstrate cryopreservation, but not dehydration, retains the native architecture of the birth tissue extracellular matrix and maintains the quantity and activity of key biological signals, including HC/HA-PTX3...[read more](#)

HC/HA-PTX3 Purified from Amniotic Membrane as Novel Regenerative Matrix: Insight into Relationship Between Inflammation and Regeneration. Review paper on the mechanism of action of birth tissue and summary of the cumulative research on the HC/HA-PTX3 complex as the key relevant tissue characteristic of the amniotic membrane and umbilical cord...[read more](#)